-
虽然绝大多数肾上腺肿瘤为无临床症状或生化检查无异常表现的良性皮质腺瘤, 但也有少部分为嗜铬细胞瘤、转移瘤或其他非皮质来源的肿瘤, 单凭常规检查方法有时难以准确判断其起源及良、恶性。本文综述PET对肾上腺肿瘤的诊断价值。
PET在肾上腺肿瘤中的应用
The diagnostic value of PET in adrenal tumors
-
摘要: 随着常规影像学诊断技术在临床上的广泛应用,肾上腺肿瘤的发现越来越多,但常规影像检查难以对所有肾上腺肿瘤做出准确定性诊断。PET是新兴的功能成像手段,对肾上腺良、恶性肿瘤鉴别的准确性高,在临床中的应用日益增多,而且PET示踪剂的迅速发展也提高了其临床应用价值。
-
关键词:
- 肾上腺肿瘤 /
- 正电子发射断层显像术 /
- 氟脱氧葡萄糖F18
Abstract: With the comprehensive apply of routine imaging techniques in clinic, more and more adrenal accidental tumors were detected.But routine imaging techniques could not confirm all of the adrenal accidental tumors.PET is a promising functional imaging modality and can differentiate correctly the benign and malignant adrenal tumors.Application of PET in clinic is gradually increased, and the advance of PET tracer improves its value. -
[1] Bagheri B, Maurer AH, Cone L, et al. Characterization of the normal adrenal gland with 18F-FDG PET/CT. J Nucl Med, 2004, 45(8): 1340-1343. [2] Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology, 2006, 238(3): 970-977. doi: 10.1148/radiol.2383042164 [3] Okada M, Shimono T, Komeya Y, et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography(FDG-PET/CT)in differentiating between benign and malignantlesions. Ann Nucl Med, 2009, 23(4): 349-354. doi: 10.1007/s12149-009-0246-4 [4] Tessonnier L, Sebag F, Palazzo FF, et al. Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?. Eur J Nucl Med Mol Imaging, 2008, 35(11): 2018-2025. doi: 10.1007/s00259-008-0849-3 [5] Jana S, Zhang T, Milstein DM, et al. FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging, 2006, 33(1): 29-35. doi: 10.1007/s00259-005-1915-8 [6] Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med, 2006, 47(1): 32-37. [7] Elaini AB, Shetty SK, Chapman VM, et al. Improved detection and characterization of adrenal disease with PET-CT. Radiographics, 2007, 27(3): 755-767. doi: 10.1148/rg.273055031 [8] Chong S, Lee KS, Kim HY, et al. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics, 2006, 26(6): 1811-1824. doi: 10.1148/rg.266065057 [9] Rao SK, Caride VJ, Ponn R, et al. F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med, 2004, 29(5): 300-302. doi: 10.1097/01.rlu.0000124008.68606.4c [10] Basu S, Nair N. 18F-FDG uptake in bilateral adrenal hyperplasia causing Cushing's syndrome. Eur J Nucl Mol Med Imaging, 2005, 32(3): 384. doi: 10.1007/s00259-004-1629-3 [11] Vikram R, Yeung HD, Macapinlac HA, et al. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. AJR Am J Roentgenol, 2008, 191(5): 1545-1551. doi: 10.2214/AJR.07.3447 [12] Narang V, Sinha T, Sandhu AS, et al. Clinically inapparent bilateral adrenal masses due to histoplasmosis. Eur Urol, 2009, 55(2): 518-521. doi: 10.1016/j.eururo.2008.09.005 [13] Kim DJ, Chung JJ, Ryu YH, et al. Adrenocortical oncocytoma displaying intense activity on 18F-FDG-PET: a case reportand a literature review. Ann Nucl Med, 2008, 22(9): 821-824. [14] Hennings J, Lindhe O, Bergström M, et al. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab, 2006, 91(4): 1410-1414. doi: 10.1210/jc.2005-2273 [15] Gross MD, Avram A, Fig LM, et al. Contemporary adrenal scintigraphy. Eur J Nucl Med Mol Imaging, 2007, 34(4): 547-557. doi: 10.1007/s00259-006-0265-5 [16] Hennings J, Hellman P, Ahlström H, et al. Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol, 2009, 69(2): 314-323. doi: 10.1016/j.ejrad.2007.10.024 [17] Gross MD, Rubello D. Something old, something new, PET in adrenalimaging. Eur J Nucl Med Mol Imaging, 2008, 35(7): 1233-1235. doi: 10.1007/s00259-008-0717-1 [18] Wadsak W, Mitterhauser M, Rendl G, et al. [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging, 2006, 33(6): 669-672. doi: 10.1007/s00259-005-0062-6 [19] Yamaga LY, Thom AF, Wagner J, et al. The effect of catecholamines on the glucose uptake in brown adipose tissue demonstrated by(18)F-FDG PET/CT in a patient with adrenal pheochromocytoma. Eur J Nucl Med Mol Imaging, 2008, 35(2): 446-447. doi: 10.1007/s00259-007-0538-7 [20] Mann GN, Link JM, Pham P, et al. [11C]metahydroxyephedrine and[18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol, 2006, 13(2): 187-197. doi: 10.1245/ASO.2006.04.022 [21] Brink I, Hoegerle S, Klisch J, et al. Imaging of pheochromocytoma and paraganglioma. Fam Cancer, 2005, 4(1): 61-68. doi: 10.1007/s10689-004-2155-y [22] Imani F, Agopian VG, Auerbach MS, et al. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med, 2009, 50(4): 513-519. [23] Taïeb D, Tessonnier L, Sebag F, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol(Oxf), 2008, 69(4): 580-586. doi: 10.1111/j.1365-2265.2008.03257.x [24] Kaji P, Carrasquillo JA, Linehan WM, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol, 2007, 156(4): 483-487. doi: 10.1530/EJE-06-0712 [25] Timmers HJ, Carrasquillo JA, Whatley M, et al. Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET. J Nucl Med, 2007, 48(12): 1940-1944. doi: 10.2967/jnumed.107.043281
计量
- 文章访问数: 2118
- HTML全文浏览量: 843
- PDF下载量: 2